PRODUCT INFORMATION



Verdinexor

Item No. 26171

CAS Registry No.:	1392136-43-4	
Formal Name:	(2Z)-3-[3-[3,5-bis(trifluoromethyl)	
	phenyl]-1H-1,2,4-triazol-1-yl]-2-	CE
	propenoic acid, 2-(2-pyridinyl)hydrazide	
Synonym:	КРТ-335	
MF:	$C_{18}H_{12}F_6N_6O$	
FW:	442.3	
Purity:	≥98%	F_3C
UV/Vis.:	λ _{max} : 232, 273 nm	
Supplied as:	A crystalline solid	N 11
Storage:	-20°C	
Stability:	≥4 years	
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.		

Laboratory Procedures

Verdinexor is supplied as a crystalline solid. A stock solution may be made by dissolving the verdinexor in the solvent of choice, which should be purged with an inert gas. Verdinexor is soluble in organic solvents such as ethanol and DMSO. The solubility of verdinexor in these solvents is approximately 11 and 88 mg/ml, respectively.

Description

Verdinexor is a reversible inhibitor of Exportin I (XPO1/CRM1) with anticancer and antiviral activities.¹⁻³ It inhibits the growth of OCI-Ly3, OCI-Ly10, and CLBL1 diffuse large B cell lymphoma (DLBCL) cells (IC₅₀s = 2.1, 41.8, and 8.5 nM, respectively).¹ Verdinexor inhibits XPO1/CRM1-mediated nuclear transport of respiratory syncytial virus (RSV) M protein when used at concentrations greater than 1 μ M.² It reduces RSV A2 replication (IC₅₀ = 0.96 μ M) without affecting viability of A549 cells (CC₅₀ = >38 μ M). In vivo, verdinexor (20 mg/kg) reduces virus shedding, pulmonary TNF- α , IL-6, MCP-1, and IFN- γ expression, and leukocyte infiltration into the bronchoalveolar space in a mouse model of influenza A viral infection.³ It also reduces viral burden in a ferret model of influenza A viral infection.

References

- 1. London, C.A., Bernabe, L.F., Barnard, S., et al. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: Results of a phase I study. PLoS One 9(2), e8758 (2014).
- 2. Jorquera, P.A., Matthew, C., Pickens, J., et al. Verdinexor (KPT-335), a selective inhibitor of nuclear export, reduces RSV replication in vitro. J. Virol. 93(4), e01684-e01718 (2018).
- 3. Perwitasari, O., Johnson, S., Yan, X., et al. Antiviral efficacy of verdinexor in vivo in two animal models of influenza A virus infection. PLoS One 11(11), e0167221 (2016).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/23/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM